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OBJECTIVES Our objective was to determine the timing of benefit with intensive statin therapy after an
acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS
and a late window in more stable patients.
BACKGROUND The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myo-
cardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin
therapy improved clinical outcomes over two years in ACS patients versus standard therapy.
The relative contributions of early or late effects to the overall clinical efficacy of intensive
therapy are presently unclear.
METHODS A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients
were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy
(pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for
recurrent ACS was determined in each group at 30 days. The composite triple and primary
end points were assessed in stable patients from six months to the end of study, after censoring
for clinical events before six months.
RESULTS The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg
versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR]  0.72; 95%
confidence interval [CI], 0.52 to 0.99; p  0.046). In stable patients, atorvastatin 80 mg was
associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group
(HR  0.72; 95% CI, 0.58 to 0.89; p  0.003).
CONCLUSIONS Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days,
consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy
provides long-term reduction in clinical events when compared with standard therapy. Thus,
ACS patients should be started in-hospital and continued long-term on intensive statin
therapy. (J Am Coll Cardiol 2005;46:1405–10) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.077Cardiology Foundation
h
b
w
r
g
t
f
E
i
r
d
t
f
i
A
e
i
s
fhe Pravastatin or Atorvastatin Evaluation and Infection
herapy–Thrombolysis In Myocardial Infarction 22 (PROVE
T-TIMI 22) trial (1) showed the clinical benefits of intensive
tatin therapy over standard therapy. We sought to evaluate
he timing of this benefit by examining the very early clinical
s well as the late effects of intensive statin therapy.
ETHODS
atient population and protocol. The design of the
ROVE IT-TIMI 22 protocol has been previously de-
cribed (1) (see the Appendix). Briefly, 4,162 patients who
From the *TIMI Study Group, Brigham and Women’s Hospital/Harvard Medical
chool, Boston, Massachusetts; the †Nottingham Clinical Research Group, Notting-
am, United Kingdom; the ‡Department of Epidemiology and Preventative Medi-
ine, Monash University, Melbourne, Australia; the §Harvard School of Public
ealth, Boston, Massachusetts; and Guy’s Hospital, London, England. The
ROVE IT-TIMI 22 trial was funded by Bristol-Myers Squibb and Sankyo. Dr. Ray
s funded by a British Heart Foundation International Fellowship.c
Manuscript received January 3, 2005; revised manuscript received March 18, 2005,
ccepted March 22, 2005.ad a total cholesterol level of 240 mg/dl and who had
een hospitalized for an acute coronary syndrome (ACS)
ithin the previous 10 days were randomly assigned in a 1:1
atio to pravastatin 40 mg or atorvastatin 80 mg daily, and
atifloxacin versus placebo, in a double-blind fashion. Pa-
ients were followed up for 18 to 36 months, with an average
ollow-up of 24 months.
nd points. The primary end point was all-cause mortal-
ty, myocardial infarction (MI), unstable angina requiring
ehospitalization, revascularization (if performed at least 30
ays after randomization), and stroke. We also evaluated a
riple composite end point (death, MI, or rehospitalization
or recurrent ACS), which is the end point commonly used
n ACS trials for evaluation of early outcomes (2). Recurrent
CS was defined as the following: readmission with isch-
mic pain associated with electrocardiograph changes, an
ncrease in cardiac markers below the threshold for diagno-
is of MI, a recurrence of cardiac pain in the hospital distinct
rom the initial episode or ischemic pain that led to cardiac
atheterization and/or revascularization. Patients readmit-
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on-cardiac chest pain were not included.
tatistical analysis. All analyses were performed on an
ntention-to-treat basis. Hazard ratio (HR) estimates and
ssociated 95% confidence intervals (CIs) were obtained
rom a Cox proportional hazards model with randomized
reatment as the only covariate, stratified by gatifloxacin or
lacebo. Clinical events from six months to the end of the
tudy were determined using a Cox regression analysis after
ensoring for clinical events before six months to generate a
onditional hazard ratio.
ESULTS
verall efficacy outcome. The composite triple end point
f death, MI, or rehospitalization with recurrent ACS was
rst evaluated over the duration of the trial (mean, two
ears). The composite end point occurred in 15.7% of
atients assigned atorvastatin 80 mg and in 20.0% of
atients assigned pravastatin 40 mg, reflecting a hazard risk
eduction of 24% (HR  0.76; 95% CI, 0.66 to 0.88; p 
.0002) (Fig. 1). Using this triple composite end point, the
enefits of intensive statin therapy with atorvastatin 80 mg
Abbreviations and Acronyms
ACS  acute coronary syndrome
CI  confidence interval
CRP  C-reactive protein
HR  hazard ratio
LDL-C  low-density lipoprotein
cholesterol
MI  myocardial infarction
PROVE IT-TIMI 22  Pravastatin or Atorvastatin
Evaluation and Infection
Therapy–Thrombolysis In
Myocardial Infarction 22
TNT  Treating to New Targets studyigure 1. Kaplan-Meier estimates of the composite end point of death, myoca
yndrome (ACS) by statin treatment. CI  confidence interval.ere seen in a large number of different subgroups (Table 1).
arly effects. To evaluate the time to benefit in the acute
hase, we first used the primary end point (Fig. 2A). At 15
ays, there was a trend to an apparent early benefit with
ntensive therapy, associated with a 15% risk reduction in
he primary end point (HR  0.85; 95% CI, 0.52 to 1.37).
t four months, the primary end point had occurred in 8.2%
f patients receiving intensive therapy versus 10.2% of
atients on standard therapy, and this had achieved statis-
ical significance (HR  0.81; 95% CI, 0.65 to 0.98; p 
.03).
Using the composite triple end point, this early benefit
gain appeared as early as 15 days after randomization,
ecame significant at 30 days, and remained stable from 30
ays onward with progressive narrowing of the confidence
ntervals (Fig. 2B). The composite end point occurred in
.0% of the intensive therapy group and in 4.2% of the
tandard therapy group, representing a 28% risk reduction at
0 days (HR 0.72; 95% CI, 0.52 to 0.99; p 0.046) with
torvastatin 80 mg (Fig. 3). The composite triple end point
as also reduced by intensive therapy in a wide range of
ubgroups even at this early 30-day time point (Table 1).
ntensive therapy lowered low-density lipoprotein choles-
erol (LDL-C) and C-reactive protein (CRP) more than
id standard therapy at 30 days and at four months
Table 2).
ate effects. From six months after ACS to the end of the
tudy, the primary end point occurred in 15.1% of patients
eceiving intensive therapy versus 17.7% of patients ran-
omized to standard therapy, resulting in an 18% reduction
n events (HR  0.82; 95% CI, 0.69 to 0.99; p  0.037).
ven using a conditional hazard analysis beginning at one
ear after ACS to the end of follow-up, there was a benefit
ith intensive therapy with an absolute event rate of 5.6%
ith intensive therapy versus 8.0% with standard therapy
HR  0.72; CI, 0.54 to 0.95; p  0.02) (Fig. 4A).rdial infarction (MI), and rehospitalization with recurrent acute coronary
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October 18, 2005:1405–10 Early and Late Benefits of High-Dose AtorvastatinSimilarly the composite triple end point, from six months
fter ACS to the end of study, occurred in 9.6% of the
ntensive therapy group and 13.1% of the standard therapy
roup, representing a 28% risk reduction (HR  0.72; 95%
I, 0.58 to 0.89; p  0.003) in favor of high-dose
torvastatin 80 mg (Fig. 5). These benefits were seen across
range of subgroups including those with a low baseline
DL-C (Table 1). Evaluation of effects more than one year
fter ACS showed that intensive therapy was also associated
ith a reduction in the composite end point (HR  0.66;
5% CI, 0.48 to 0.92; p  0.01) (Fig. 4B).
able 1. Risk of Death, Myocardial Infarction, or Rehospitalizati
tatin Regimen for the Entire Study, at 30 Days, and Between 6
Overall
Subgroup* HR (95% CI)† p
ge 58 yrs 0.91 (0.74–1.1) 0.3
ge 58 yrs 0.62 (0.5–0.77) 0.0001
ale 0.78 (0.66–0.91) 0.003
emale 0.7 (0.52–0.95) 0.02
iabetics 0.68 (0.51–0.9) 0.007
on-diabetics 0.77 (0.65–0.92) 0.003
mokers 0.78 (0.66–0.92) 0.003
on-smokers 0.69 (0.52–0.94) 0.02
ypertension 0.81 (0.67–0.98) 0.03
o hypertension 0.68 (0.54–0.85) 0.0009
A 0.72 (0.56–0.91) 0.007
STEMI 0.78 (0.6–1.01) 0.06
TEMI 0.78 (0.61–1.01) 0.06
DL 125 mg/dl 0.6 (0.45–0.81) 0.0008
DL 125 mg/dl 0.83 (0.7–0.99) 0.04
DL 40 mg/dl 0.72 (0.58–0.9) 0.005
DL 40 mg/dl 0.8 (0.66–0.98) 0.03
rior statin 0.78 (0.6–1.01) 0.06
o prior statin 0.75 (0.62–0.89) 0.001
Median age  58 years, Smoking is defined as current or prior history. †Atorvastati
s the only covariate, stratified by gatifloxacin or placebo).
CI  confidence interval; HDL  high-density lipoprotein; HR  hazard rati
nfarction; STEMI  ST-segment elevation myocardial infarction; UA  unstable
igure 2. (A) Cumulative hazard ratios (HRs) of the primary end point of
evascularization 30 days, and stroke showing the relative benefit as early
Rs of composite triple end point of death, myocardial infarction, or rehospitaliz
s early as 15 days and achieving statistical significance by 30 days. CI  confiISCUSSION
cute coronary syndrome is increasingly recognized as a
iffuse process involving the entire coronary vasculature (3),
nd although therapeutic revascularization by percutaneous
oronary intervention may address the culprit lesion, recur-
ent events may reflect disease progression or instability
lsewhere in the vascular tree. Although anti-thrombotic
nd anti-platelet agents “passivate” the thrombotic compo-
ents of ACS, their effects on plaque stabilization or
therosclerosis disease progression are less clear. Therefore,
ith Acute Coronary Syndrome in Different Subgroups by
ths and End of Study
andomization to 30 Days 6 Months to End of Study
(95% CI) p HR (95% CI) p
(0.61–1.58) 0.9 0.86 (0.64–1.14) 0.3
(0.34–0.84) 0.007 0.58 (0.41–0.82) 0.002
(0.47–1) 0.05 0.7 (0.55–0.91) 0.006
(0.44–1.54) 0.5 0.76 (0.48–1.2) 0.2
(0.25–1.03) 0.06 0.72 (0.47–1.11) 0.1
(0.55–1.14) 0.2 0.7 (0.54–0.9) 0.006
(0.4–0.88) 0.01 0.74 (0.58–0.95) 0.02
(0.6–1.88) 0.8 0.64 (0.41–1.02) 0.06
(0.52–1.25) 0.4 0.77 (0.58–1.02) 0.07
(0.35–0.98) 0.04 0.64 (0.45–0.9) 0.01
(0.31–1.06) 0.08 0.66 (0.47–0.93) 0.02
(0.38–1.19) 0.2 0.91 (0.6–1.36) 0.6
(0.52–1.5) 0.7 0.65 (0.43–0.97) 0.03
(0.15–0.64) 0.002 0.66 (0.42–1.04) 0.07
(0.63–1.36) 0.7 0.76 (0.59–0.99) 0.04
(0.35–0.99) 0.05 0.73 (0.51–1.02) 0.07
(0.52–1.24) 0.3 0.75 (0.58–0.96) 0.05
(0.44–1.45) 0.5 0.72 (0.5–1.03) 0.07
(0.46–1.01) 0.06 0.71 (0.54–0.94) 0.02
s pravastatin, determined by a Cox proportional hazards model (with the treatment
L  low-density lipoprotein; NSTEMI  non–ST-segment elevation myocardial
.
h, myocardial infarction, unstable angina requiring hospitalization, urgent
days and achieving statistical significance by four months. (B) Cumulativeon W
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Early and Late Benefits of High-Dose Atorvastatin October 18, 2005:1405–10tabilization of vulnerable plaques has emerged as an im-
ortant target for systemic therapy. The biological effects
f statins on inflammation, endothelial function, and
oagulation (the so-called pleiotropic effects) are consis-
ent with actions that would lead to plaque stabilization
3). The results of this analysis from the PROVE
able 2. Effect of Statin Therapy on LDL-C and CRP
Statin Regimen Baseline 30 Days 4 Months
DL-C, mg/dl (mean)
Pravastatin, 40 mg 106 88 97
Atorvastatin, 80 mg 106 60 67
p NS 0.001 0.001
RP, mg/l (median)
Pravastatin, 40 mg 11.9 2.3 2.1
Atorvastatin, 80 mg 12.2 1.6 1.3
p NS 0.001 0.001
RP  C-reactive protein; LDL-C  low-density lipoprotein C.
igure 3. Kaplan-Meier estimates of the composite end point of death,
yndrome (ACS) by statin treatment from randomization to 30 days. CIigure 4. (A) Conditional hazard ratios (HRs) for the primary end point in each
n each year of the trial.T-TIMI 22 trial show that intensive statin therapy with
torvastatin 80 mg, when compared with standard ther-
py with pravastatin 40 mg, is associated with a signifi-
ant reduction in the composite clinical end point of
eath, MI, or rehospitalization for recurrent ACS as early
s 30 days after randomization after ACS. Indeed a trend
n favor of intensive therapy was already noted at 15 days
fter randomization (Fig. 2). In addition, in patients
table for 6 or even 12 months, continued intensive statin
herapy resulted in a further significant reduction in both
he primary end point and the triple composite end point
hrough follow-up (mean of 24 months). A similar
nding has now been seen in stable revascularized pa-
ients with coronary artery disease in the Treating to New
argets (TNT) trial (4).
The early benefits of intensive statin therapy observed in
he PROVE IT-TIMI 22 trial are in sharp contrast with the
rdial infarction (MI), or rehospitalization with recurrent acute coronary
fidence interval.year of the trial. (B) Conditional HRs for the composite triple end point
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October 18, 2005:1405–10 Early and Late Benefits of High-Dose Atorvastatinrogram on the Surgical Control of Hyperlipidemias
POSCH) trial (5), in which ileal bypass was associated with
dramatic early reduction in LDL-C but no early reduction
n clinical events. Also, in patients with stable coronary
rtery disease, the apparent benefit from statin therapy is
requently delayed beyond one year (6). Our findings
uggest that the clinical benefits observed in ACS patients
ccur before the greater reductions in LDL-C with inten-
ive statin therapy are likely to have had any significant
ffect on disease progression. In the PROVE IT-TIMI 22
rial, the median CRP level at 30 days was 1.6 mg/l in the
torvastatin 80 mg group compared with 2.3 mg/l in the
ravastatin 40 mg arm (p  0.001), supporting greater early
nti-inflammatory pleiotropic effects with intensive statin
herapy (7).
In the PROVE IT-TIMI 22 trial, stable patients who
ere free of clinical events at six months showed a similar
enefit in favor of intensive statin therapy (atorvastatin, 80
g) compared with standard-dose statin therapy (pravasta-
in, 40 mg) for both the primary and the composite triple
nd points. This suggests that there is continuing benefit
rom the use of intensive statin therapy beyond the acute
eriod. The long-term clinical benefits of statin therapy
ersus placebo are thought to be related to the greater
eduction in LDL-C, which may retard progression of
therosclerotic disease (8). Recent trials using clinical (1,7)
nd ultrasound end points (8) have shown that intensive
herapy achieves a greater reduction in LDL-C and CRP
evels compared with standard statin therapy, and that these
re associated with a reduction in clinical events and in the
ate of progression of atherosclerosis. After ACS, potential
enefits from other pleiotropic effects such as improved
ndothelial function could also play an important role in
mproving outcome more than six months after ACS. The
resent analysis does not differentiate between the relative
ontributions of the lipid lowering from the pleiotropic
igure 5. Kaplan-Meier estimates of the composite end point of death,
yndrome (ACS) by statin treatment, in patients free from clinical eventsffects of statins in reducing long-term events in stableatients, and both processes are likely to be important. This
s supported by the observations in the PROVE IT-TIMI
2 trial that lowering the CRP level was of equal importance
s lowering the LDL-C level in reducing adverse outcomes
7).
tudy limitations. The conditional analysis of the late
enefits (censoring at six months) should be considered
bservational and not as part of a randomized analysis.
ONCLUSIONS
he PROVE IT-TIMI 22 trial shows that intensive versus
tandard statin therapy leads to a reduction in clinical events
ithin 30 days after an ACS, within a time window
onsistent with the early pleiotropic effects seen with statins.
n stable patients, intensive statin therapy is also associated
ith a long-term reduction in clinical events during follow-
p. Thus, intensive statin therapy provides two windows of
ardioprotection in patients with ACS. Treatment of pa-
ients with ACS should begin in-hospital with high-dose
ntensive stain therapy to achieve these early clinical benefits
nd should be continued long-term.
eprint requests and correspondence: Dr. Christopher P. Can-
on, TIMI Study Group, 350 Longwood Avenue, 1st Floor,
oston, Massachusetts 02115. E-mail: cpcannon@partners.org.
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